Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since ADGRE5 plays an important role in tumor cell formation, metastasis and invasion, it might also be instrumental to better understand the different pathobiology of BL and DLBCL and help to explain discrepant clinical characteristics of BL and DLBCL.
|
30953469 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study suggested that the overexpression of CD97 in cervical cancer was correlated with the aggressiveness of the tumour and that CD97 might be an independent poor prognostic factor for cervical cancer patients.
|
30883974 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma.
|
29704239 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings support targeted blockade of tumor CD97 as an approach to ameliorate metastatic spread.
|
29669286 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126.
|
24274104 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumors were strongly CD97-positive, independent of the underlying histological subtype, suggesting high sensitivity of CD97 for this tumor.
|
24949957 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 is a tumor-associated adhesion-class G-protein-coupled receptor involved in modulating cell migration.
|
25174588 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of transgenic CD97 in thyroid epithelium led to elevated ERK phosphorylation and increased numbers of Ki67+ cells in developing tumors.
|
22797060 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This phenotype may explain the discrepancy in survival between high and low CD97-expressing tumors.
|
23658650 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The study further lightened the tumor promoting role of CD97 small isoform in cancer progression and indicated the possible suppressive properties of the full length isoform of CD97.
|
20428763 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show here that CD97alpha promotes angiogenesis in vivo as demonstrated with purified protein in a directed in vivo angiogenesis assay (DIVAA) and by enhanced vascularization of developing tumors expressing CD97.
|
15576472 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was strong correlation between the distribution patterns of CD97(stalk) and CD55 on tumor tissues (r=0.73, P<0.05).
|
16130195 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoprecipitation of CD97 from the Colo 205 tumor cell line revealed the established 78 and 83 kDa products, while a 52 and 57 kDa band were obtained from smooth muscle cells.
|
15386373 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast to CD97, which is found in most colorectal adenocarcinomas, only 8 of 81 of these tumors expressed EMR2.
|
12761622 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, intralobular and interlobular pancreatic ducts were CD97+.All tumors were EMR2-.
|
12428789 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD97 was absent or only weakly present in patients with postoperative T1 tumors but increased greatly with the progression to postoperative T4 tumors.
|
9135025 |
1997 |